01 / DUAL ACTIVE BLEND
Precision Micro-Dose Blending
Each tablet contains Escitalopram 5 mg and Clonazepam 0.25 mg with strict active assay uniformity and rapid dissolution complying with Indian Pharmacopoeia standards.
Blessme · Antidepressants & Anxiolytics
Escitalopram + Clonazepam Tablets - ESICARE-PLUS-H
ESICARE-PLUS-H is a precision-calibrated oral tablet combining Escitalopram Oxalate IP equivalent to Escitalopram 5 mg with Clonazepam IP 0.25 mg by Blessme, Dellwich Lifescience LLP. Formulated as an optimal initial titration formulation, it provides dual serotonergic mood elevation and GABAergic limbic calming to overcome the initial latency of antidepressant therapy while minimizing daytime sedation.
Initial Titration Synergy
Narcotic / Schedule H
Pan-India Supply
Product SpecificationsAbout Escitalopram + Clonazepam
About Escitalopram + Clonazepam
(ESICARE-PLUS-H)
Detailed pharmaceutical specifications, active API monograph compliance, low-dose SSRI-GABA synergy, and 5x4x10 blister packaging details for ESICARE-PLUS-H.
Blessme · Antidepressant & Anxiolytic
Escitalopram + Clonazepam - ESICARE-PLUS-H
ESICARE-PLUS-H unites 5 mg Escitalopram with 0.25 mg Clonazepam. Formulated as a gentle starting regimen for depression comorbid with anxiety, it bridges the initial 2-week SSRI lag phase while preventing anxiety spikes.
5 mg Escitalopram Gently Elevates Synaptic Serotonin 0.25 mg Clonazepam Provides Immediate Day-1 Anxiolysis Ideal Starting Titration Dose for Sensitive Patients 5x4x10 Blister Strip Format for Enhanced Foil Protection Strict Indian Pharmacopoeia Quality Standards
- Product Brand Name
- ESICARE-PLUS-H
- Active Pharmaceutical Ingredients
- Escitalopram Oxalate IP eq. to Escitalopram 5 mg + Clonazepam IP 0.25 mgVerified IP
- Therapeutic Class
- Neuropsychiatric Antidepressant (SSRI) & Anxiolytic (Benzodiazepine)
- Dosage Form
- Oral Solid Compressed Tablet
- Strength Formulation
- 5 mg Escitalopram + 0.25 mg Clonazepam (Half-Strength Titration)
- Packaging Standard
- 5x4x10 Blister Strips (200 Tablets per Box)
- Regulatory Category
- Narcotic Drug
- Marketing Division
- Blessme · Neuro & Psychiatric Products
- Manufacturing Standard
- WHO-GMP & ISO 9001:2015 Certified Clean-Room Compression
- Storage Condition
- Store below 25°C in a dry place. Protect from light and moisture.
- Country of Origin
- India
Clinical & Commercial MonographEscitalopram + Clonazepam Tablet & ESICARE-PLUS-H
Escitalopram + Clonazepam Tablet & ESICARE-PLUS-H
Complete Medical & Supply Guide
In-depth pharmacological evaluation of Escitalopram 5 mg + Clonazepam 0.25 mg tablets, marketed as ESICARE-PLUS-H by Blessme (Dellwich Lifescience LLP). Covers dual serotonergic and GABAergic mechanisms, therapeutic bridging, and pharmaceutical supply across India.
What is ESICARE-PLUS-H (Escitalopram 5 mg + Clonazepam 0.25 mg)?
ESICARE-PLUS-H is a fixed-dose oral neuropsychiatric tablet engineered for the initiation phase of mixed anxiety and depressive disorders. While Escitalopram works on long-term mood regulation, Clonazepam provides rapid calming from the very first dose.
When doctors and hospitals search for Escitalopram Clonazepam 5mg tablet or low-dose SSRI anxiolytic combination, they look for reliable blend uniformity and clean titration profiles. ESICARE-PLUS-H delivers these qualities through automated clean-room manufacturing under WHO-GMP compliance.
Clinical Uses & Evidence-Based Indications
Approved neurological and psychiatric indications for ESICARE-PLUS-H include:
- Initiation Therapy in GAD: Fast relief of psychic worry and somatic tension without high-dose side effects.
- Comorbid Depression with Anxiety: Manages mixed symptoms while mitigating SSRI-induced initial jitteriness.
- Panic Disorder with Agoraphobia: Aborts anticipatory panic during the initial therapeutic window.
- Social Anxiety Disorder: Reduces situational panic and performance-related apprehension.
- Geriatric & Sensitive Patients: Half-strength titration to assess tolerability with minimal drowsiness.
Neurochemical Mechanism of Action: Dual Serotonergic & GABAergic Synergy
Escitalopram is the pure S-enantiomer of citalopram, functioning as an allosteric selective serotonin reuptake inhibitor (SSRI). By binding with high selectivity to the primary and allosteric sites on the serotonin transporter (SERT), it inhibits 5-HT reuptake, steadily elevating serotonin levels in synaptic clefts across the prefrontal cortex and hippocampus.
Simultaneously, Clonazepam 0.25 mg acts as a positive allosteric modulator on the GABAA receptor-chloride ion channel complex. By increasing chloride influx, it hyperpolarizes limbic neurons, immediately terminating acute anxiety and preventing the initial paradoxical agitation often seen when starting SSRIs alone.
Formulation Comparison: ESICARE-PLUS-H vs. ESICARE-LS vs. ESICARE-PLUS
Clinical criteria for selecting between the formulations:
- ESICARE-PLUS-H (5 mg + 0.25 mg): Starting titration dose for sensitive patients, geriatric individuals, or mild anxiety-depression overlap.
- ESICARE-LS (10 mg + 0.25 mg): Standard therapeutic antidepressant dose (10 mg) with micro-dose anxiolytic cover (0.25 mg) for long-term maintenance.
- ESICARE-PLUS (10 mg + 0.5 mg): Full-strength antidepressant with higher-potency anxiolytic (0.5 mg) for severe panic crises and severe agitation.
Dosage Guidelines & Administration Method
ESICARE-PLUS-H must be taken strictly in accordance with medical advice:
- Starting Dose: Typically 1 tablet once daily, preferably in the morning or at night with water.
- Dose Titration: If required, may be titrated to ESICARE-LS or ESICARE-PLUS after 1 to 2 weeks under medical supervision.
- With or Without Food: Can be administered with meals to minimize potential initial mild nausea.
- Tapering Protocol: Do not discontinue abruptly; gradual tapering prevents discontinuation phenomena.
Critical Safety Warning - Schedule H / Narcotic Controlled Substance
ESICARE-PLUS-H contains Clonazepam, which carries potential for dependence and habit formation with prolonged therapy. Do not consume alcohol during therapy. Contraindicated with monoamine oxidase inhibitors (MAOIs) due to risk of serotonin syndrome. Dispensed strictly against a valid medical prescription.
Quality & Production
Pharmaceutical Quality Assurance & Compliance
ESICARE-PLUS-H is manufactured in WHO-GMP certified facilities adhering to Schedule M protocols, ensuring micro-blend homogeneity and maximum packaging stability.
02 / PROTECTIVE PACKAGING
High-Barrier Blister Foil
Tamper-evident, tropicalized blister strips prevent moisture ingress and light-induced degradation, ensuring active ingredient stability across diverse Indian climates.
03 / PHARMACOPOEIA DOSSIERS
COA & Batch Testing Records
Every batch is backed by authenticated Certificates of Analysis (COA), disintegration profiles, assay validation data, and Material Safety Data Sheets for hospital audits.
04 / WHO-GMP COMPLIANCE
Schedule M Manufacturing
Produced in state-of-the-art accredited manufacturing units in Gujarat adhering to automated compression, online check-weighing, and Good Laboratory Practices (GLP).
Clinical Profile & Precautions
Approved Indications & Regulatory Guidelines
Prescribing guidance, contraindications, and drug interactions for Escitalopram 5 mg + Clonazepam 0.25 mg tablets.
Prescription-Only Schedule H / Narcotic Medication Notice
ESICARE-PLUS-H is a Schedule H prescription drug. Not for OTC sale. Do not consume alcohol during therapy. Exercise caution when driving or operating machinery.
Clinical Indications Profile
Approved neurological and psychiatric indications for ESICARE-PLUS-H:
- Initiation in GAD: Prompt reduction in excessive worry, autonomic arousal, and restlessness.
- Mixed Anxiety-Depression: Elevates mood while calming psychic fear.
- Panic Disorder: Protects against acute panic surges during early antidepressant therapy.
- Social Phobia: Relieves situational social anxiety and anticipatory panic.
Contraindications & Precautions
Key contraindications and monitoring requirements:
- MAOI Interaction: Never use concurrently with MAOIs; observe a 14-day washout period.
- QTc Prolongation: Caution in patients with known cardiac conduction abnormalities.
- Alcohol Prohibition: Dangerous synergism leading to severe hypotension and CNS depression.
- Suicidality Monitoring: Close monitoring required in young adults during initial weeks of therapy.
Manufacturing & Marketing
Dellwich Lifescience LLPBlessme · Neuro & Psychiatric Division
About Dellwich Lifescience
Trusted Neuro & Psychiatric Pharmaceutical Manufacturer in Ahmedabad, Gujarat
Dellwich Lifescience LLP is an established pharmaceutical company based in Science City, Ahmedabad, Gujarat, dedicated to advanced formulation technology, uncompromising quality assurance, and ethical healthcare supply. Through our specialized neurology division, Blessme, we manufacture and market superior neuro-psychiatric treatments, including ESICARE-PLUS-H (Escitalopram 5 mg + Clonazepam 0.25 mg Tablets).
We support PCD pharma franchise partners, hospital supply chains, and contract manufacturing clients across India with guaranteed supply security, validated product dossiers, and prompt dispatch.
Commercial PartnershipsESICARE-PLUS-H Supply &
ESICARE-PLUS-H Supply &
Pharmaceutical Distribution
Whether you are seeking ESICARE-PLUS-H for district monopoly PCD franchise distribution, third-party contract manufacturing, or hospital bulk procurement, Dellwich Lifescience LLP delivers dependable supply and competitive trade margins.
Exclusive Monopoly PCD Franchise
Secure district-level monopoly marketing rights for ESICARE-PLUS-H and the Blessme neuropsychiatry range with visual aids, product glossaries, and promotional input support.
Third-Party Contract Manufacturing
Turnkey manufacturing solutions for pharmaceutical marketing companies with flexible batch runs, rapid production turnaround, and full regulatory dossier support from Ahmedabad.
Hospital & Institutional Procurement
Direct bulk pharmaceutical supply agreements for multispecialty hospital chains, psychiatric nursing homes, and institutional medical tenders with prompt pan-India logistics.
Blessme · ESICARE-PLUS-H
Why Choose ESICARE-PLUS-H Tablets?
When sourcing Escitalopram Clonazepam tablets in India, ESICARE-PLUS-H by Blessme provides exceptional clinical efficacy, reliable blister packaging, and comprehensive B2B franchise support.
WHO-GMP Certified Purity
Manufactured in accredited facilities using IP grade APIs, ensuring exact active content uniformity and fast disintegration.
High-Barrier Blister Packaging
Tamper-evident, moisture-resistant blister strips protect tablets from ambient humidity and transport friction.
Pan-India Dispatch from Ahmedabad
Direct factory dispatch with GST invoicing, verified batch COA, and dependable logistics coverage across all Indian states.
Monopoly PCD Franchise Rights
Exclusive district-level franchise rights for ESICARE-PLUS-H and the Blessme portfolio with promotional visual aids.
Comprehensive Regulatory Dossiers
Certificates of Analysis (COA), stability testing data, and MSDS readily available for institutional audits and tenders.
Direct Manufacturer Support
Direct access to Dellwich Lifescience product specialists for quick quotes, customized bulk orders, and customer assistance.
Common Questions
Frequently Asked Questions about ESICARE-PLUS-H
Authoritative answers to clinical, commercial, dosage, and regulatory questions regarding Escitalopram + Clonazepam tablets.
What is ESICARE-PLUS-H and what does it contain?
ESICARE-PLUS-H is a fixed-dose oral prescription tablet from the Blessme division of Dellwich Lifescience. It contains Escitalopram Oxalate IP equivalent to Escitalopram 5 mg and Clonazepam IP 0.25 mg. The 'H' denotes Half-strength, ideal for starting therapy in anxiety and depression with minimal initial side effects.
Why is Clonazepam added to Escitalopram?
Escitalopram is an SSRI that requires 2 to 4 weeks to achieve full therapeutic mood elevation, and may cause transient initial restlessness. Clonazepam provides rapid, immediate calming and panic relief from day one, bridging the therapeutic gap until Escitalopram takes effect.
What is the difference between ESICARE-PLUS-H and ESICARE-LS?
ESICARE-PLUS-H contains Escitalopram 5 mg + Clonazepam 0.25 mg (a lower initiating dose for sensitive patients or mild anxiety). ESICARE-LS contains Escitalopram 10 mg + Clonazepam 0.25 mg (the standard therapeutic maintenance dose for depression with low-dose anxiolytic support).
What is the difference between ESICARE-PLUS-H and ESICARE-PLUS?
ESICARE-PLUS contains full therapeutic doses of both agents (Escitalopram 10 mg + Clonazepam 0.5 mg), indicated for severe panic disorder and major depression with severe agitation. ESICARE-PLUS-H provides half the strength of both components for gentler titration.
When should ESICARE-PLUS-H be taken?
Clinicians usually recommend taking ESICARE-PLUS-H once daily, either in the morning or at bedtime, preferably at the same time each day with a glass of water.
Will ESICARE-PLUS-H cause daytime sleepiness?
Because the Clonazepam dose is calibrated at 0.25 mg, most patients experience anxiety relief without heavy sedation. However, mild drowsiness can occur during early days of therapy. Patients should exercise caution when driving or operating machinery.
Can ESICARE-PLUS-H be stopped suddenly?
No. Abrupt stoppage can lead to withdrawal symptoms (such as dizziness, irritability, sensory disturbances) and rebound anxiety due to discontinuation of both the SSRI and benzodiazepine. Tapering under psychiatric guidance is essential.
Can I drink alcohol while taking ESICARE-PLUS-H?
No. Alcohol consumption significantly increases CNS depressant effects, causing severe drowsiness, impaired psychomotor performance, and increased risk of respiratory depression.
Is ESICARE-PLUS-H habit-forming?
The Clonazepam component belongs to the benzodiazepine class and carries potential for dependence when taken continuously over long periods. Clinicians typically reassess therapy after 4 to 8 weeks to consider tapering the benzodiazepine component.
What are common side effects of ESICARE-PLUS-H?
Common side effects include mild nausea, dry mouth, drowsiness, fatigue, changes in sleep, or mild headache. These usually diminish as the body adjusts over the first two weeks of treatment.
Can pregnant women take ESICARE-PLUS-H?
Use during pregnancy is generally avoided unless clearly needed and evaluated by a medical specialist, as both Escitalopram and Clonazepam can pose risks to the developing fetus.
How is ESICARE-PLUS-H packaged?
ESICARE-PLUS-H is supplied in premium 5x4x10 blister strips (200 tablets per box) manufactured with moisture-barrier foil to guarantee extended shelf life across all Indian climate conditions.
How can distributors apply for PCD franchise monopoly for ESICARE-PLUS-H?
Pharmaceutical distributors and stockists can submit an enquiry through our online form below or contact our neuropsychiatry franchise desk at +91 99099 31992 for monopoly territory allocation.
Where does Dellwich Lifescience manufacture ESICARE-PLUS-H?
Manufactured in WHO-GMP certified facilities located in Gujarat, adhering to strict Indian Pharmacopoeia standards and automated validation procedures.
Direct Pharmaceutical Enquiry
Need Verified Information or Bulk Supply of ESICARE-PLUS-H?
Connect directly with Dellwich Lifescience LLP for trade pricing, district monopoly PCD rights, third-party manufacturing, or institutional hospital tender supplies.
Direct Manufacturer Pricing & Transparent MOQ
Exclusive PCD Monopoly Rights for Designated Districts
Fast Dispatch from Ahmedabad with GST Invoicing
Comprehensive Marketing, Visual Aids & Promotional Inputs
Quick Assistance & Orders
Enquire About ESICARE-PLUS-H
Get wholesale pricing, PCD franchise monopoly rights, and technical documentation for Escitalopram 5 mg + Clonazepam 0.25 mg Tablets.